Safety study of SST001 in Parkinson's and MSA patients
Part of Brain & nervous system clinical trials.
This is an early-stage study testing a new experimental medicine called SST001 in people with Parkinson's disease (PD) and multiple system atrophy (MSA), as well as healthy volunteers. The study checks whether SST001 is safe, how the body processes it, and where it goes in the body using imaging scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 40 years old
- Have adequate organ function (liver, kidney, heart working well enough)
- Be willing and able to follow study procedures, including imaging scans
- Use proper contraception methods if you can become pregnant
- Not be pregnant or breastfeeding
- Not have active hepatitis B, hepatitis C, or HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects data from people with Parkinson's disease or multiple system atrophy (MSA) to better understand these conditions. You will have blood, saliva, optional spinal fluid tests, and brain scans (MRI, PET/SPECT).
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This early-stage research trial tests a new brain-imaging tracer called [11C]MODAG-005 to help doctors better understand Parkinson's disease (PD) and multiple system atrophy (MSA). You would undergo PET/CT and MRI scans twice, a few weeks apart, to see how reliable the imaging is.
Hear when a new Multiple System Atrophy (MSA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.